Navigation Links
PRoFESS(R) Results Announced at XVII European Stroke Conference
Date:5/14/2008

RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Results of the PRoFESS(R) (Prevention Regimen For Effectively avoiding Second Strokes) trial -- the world's largest clinical research study for secondary stroke prevention -- were presented today at the XVII European Stroke Conference in Nice, France. In the study, recurrent stroke event rates for Aggrenox(R) and clopidogrel were similar (9.0% and 8.8%, respectively; HR 1.01, 95% CI 0.92-1.11). The study did not meet its primary endpoint of non-inferiority for AGGRENOX versus clopidogrel.(1)

In further exploratory analysis of the main secondary endpoint of the composite of stroke, myocardial infarction or vascular death, AGGRENOX and clopidogrel showed similar outcomes (13.1% versus 13.1%).(1)

In PRoFESS, the AGGRENOX arm had a higher number of hemorrhagic strokes compared to clopidogrel (0.8% and 0.4%, respectively) while ischemic stroke recurrences were less frequent in the AGGRENOX arm compared to the clopidogrel arm (7.7% and 7.9%, respectively).(1)

A post-hoc analysis showed comparable numbers of death and disabling strokes and a similar neurological outcome as measured by the modified Rankin Scale(2) at three months after the recurrent stroke and at the end of the PRoFESS trial between the two treatment arms.(1)

Major hemorrhagic events were observed more frequently in the AGGRENOX group compared with clopidogrel (4.1% versus 3.6%; HR 1.15, 95% CI 1.00-1.32). The benefit-risk ratio expressed as the combination of recurrent stroke and major hemorrhage was not significantly different between AGGRENOX and clopidogrel (11.7% and 11.4% respectively; HR 1.03, 95% CI 0.95-1.11).(1)

"Given the high prevalence of stroke and recurrent stroke in aging societies, physicians need a range of treatment options so they can offer patients a regimen tailored to their individual needs," said Professor Hans-Christoph Diener, MD, University of Essen, Germany, one of the three principal investigator
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

10

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
3. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
4. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
5. DATATRAK International Reports First Quarter Results for 2008
6. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
7. Exelixis Announces First Quarter 2008 Financial Results
8. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
9. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
10. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
11. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... GROVE, Minn. , May 22, 2013 ... announced the successful completion of its global ... topiramate), an internally developed program for the ... company,s proprietary formulation technology.  USL255 is specifically ... reduce fluctuations in topiramate blood levels observed ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... 22, 2013 Space Girl Organics ... sponsor for this weekend's I Talk to Strangers Miracle ... am at Cocoa Riverside Park in Cocoa, FL. The event ... Talk to Strangers social movement. , As a sponsor, Space ... to participate in the event. Additionally, they are providing bananas ...
(Date:5/22/2013)... Pamela Isom, President and CEO of ICE ... 2013 Women of Influence Award in recognition for her ... reception took place on Thursday, May 2 at The ... particularly humbling for the 5,000 people ICE Safety Solutions ... to recognize the four to nine lives saved per ...
(Date:5/22/2013)... 2013 Homeopathic Vibes is implementing new store ... to the store during normal hours. On Wednesdays, they will ... to accommodate some of our patients who work shifts that ... or on Saturdays,” says owner and homeopathic consultant, Harminder Singh. ... 6 p.m. Monday through Friday; weekends are by appointment only. ...
Breaking Medicine News(10 mins):Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:Homeopathic Vibes Now Open Late on Wednesdays 2
... YORK, NY, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - ... acquires, and develops novel drug targets that disrupt the ... a patent for a potential blockbuster drug target that ... a tailor-made lipid which induces cell death in breast ...
... Immediately after President Obama,s speech to a Joint Session of ... nation,s top political, legislative and communications strategists -- representing a ... and public relations. , , The ... very happy with the speech, but most reactions were short ...
... ... rights to a suite of intellectual property owned by Spherofix AB. , ... Charlotte, NC (PRWEB) September 10, ... acquired exclusive rights to a suite of intellectual property owned by Spherofix AB., , ...
... Netherlands, September 10 The Danish Council,for Strategic Research ... Thursday, September 10. The purpose of their visit is ... and the concrete results,that are being booked by this ... cited TI Pharma as a prime example of public-private,collaboration ...
... Sept. 9 Family Research Council President Tony Perkins made ... a joint session of Congress. , , ... , Tomorrow night in a live webcast at ... address. Perkins will be joined by Senator Jim DeMint (R-SC), ...
... , WASHINGTON, Sept. 9 America,s ... Ignagni, President and CEO: , , "We agree ... plans last year did something industries rarely do: stepped up and ... American people. We proposed health insurance reform to guarantee coverage ...
Cached Medicine News:Health News:GENova files patent for new breast cancer treatment 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 3Health News:Kapstone Medical Acquires Exclusive License to New Orthopedic Technology 2Health News:Dutch Top Institute Pharma Attracts International Interest 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... ACL 10000 allows you to maximize your ... staff are limited. This fully automated system ... analysis and advanced robotics, to ensure testing ... the ACL 10000 is backed by our ...
The SYNCHRON CX7-S workstation offers a broad menu, advanced data management and more. Targeted to the mid-volume lab, the CX7-S is easy to use, easy to maintain and easy to acquire....
... CX5 Delta takes the automation and ... and adds the benefit of electrolyte ... chemistry system for the low- to ... capabilities and continuous sample loading. The ...
Medicine Products: